Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- XOMA (US) LLC
- Target Recruit Count
- 68
- Registration Number
- NCT00513214
Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- XOMA (US) LLC
- Target Recruit Count
- 6
- Registration Number
- NCT00454155
Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-01-16
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- XOMA (US) LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00051675
- Locations
- 🇺🇸
Jack D. Weiler Hospital of the Albert Einstein College of Medicine, Bronx, New York, United States
Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-01-16
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- XOMA (US) LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00051662
Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-04-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- XOMA (US) LLC
- Registration Number
- NCT00034203
- Locations
- 🇺🇸
Wallace Rheumatic Study Center, Los Angeles, California, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸The San Diego Arthritis and Osteoporosis Medical Clinic, San Diego, California, United States
© Copyright 2024. All Rights Reserved by MedPath